Anthropic opens $50,000 Claude-credit grants for rare disease research

Anthropic opened applications for a new sub-grant competition under its AI for Science program, offering researchers and early-stage biotech companies up to $50,000 in Claude API credits to work on rare genetic diseases.

What's new

According to Anthropic's announcement, "Accepted applicants will receive up to $50,000 in Claude credits over six months, with the goal of building a community of researchers looking into how AI can reshape our understanding of rare disease." Applications close August 2, 2026: "We will be accepting applications through August 2, 2026 at 11:59 PM PST."

The program runs two tracks:

• Track One (basic science) — pairs clinical researchers, patient organizations, and data scientists to find mechanisms shared across rare diseases. A key partner is the Monarch Initiative, an international consortium that maintains the Mondo Disease Ontology and Monarch Knowledge Graph, and has built DisMech, described as "a new agent-friendly mechanistic disease classification library" where Claude analyzes case reports, variant databases, and registry schemas to surface disease similarities.
• Track Two (biotech) — supports early-stage companies trying to compress the one-to-two-year gap between genetic diagnosis and patient treatment, targeting regulatory documentation, therapeutic strategy selection, and identifying shared mechanisms that could enable basket trials instead of per-therapy approvals.

Anthropic points to existing users of Claude in this space as a preview of what the grants are meant to scale: Every Cure for drug repurposing, the Centre for Population Genomics for variant classification drafts, and the Violet Research Institute for FDA guidance navigation, bioinformatics pipelines, and regulatory filings.

Context

The grants are a narrower follow-on to the AI for Science program Anthropic launched last spring: "Last spring, we announced Anthropic's AI for Science program, an initiative designed to accelerate scientific research and discovery through access to our API." This rare disease call is the first thematic sub-grant inside that broader program. It also lands one day after Anthropic said it would launch a $200 million Economic Futures Research Fund and the same week the company donated another $20 million to Public First Action for AI policy education — part of a broader July push into funded external research and public-interest spending.

Rare disease is a natural target for this kind of program: an estimated 400 million people worldwide live with one of more than 7,000 rare diseases, but small, geographically scattered patient populations make it hard to build registries, identify therapeutic targets, or design clinical trials using conventional methods.

Why it matters

A $50,000 credit grant is small in isolation, but the structure signals how Anthropic wants to compete for scientific mindshare against Google DeepMind's AlphaFold/AlphaGenome push and OpenAI's science partnerships: not with a single splashy model release, but with recurring, themed grant calls that seed case studies (Every Cure, Monarch Initiative) it can point to later. For rare disease researchers and small biotechs, six months of API access lowers the cost of testing whether Claude can meaningfully speed up literature synthesis or regulatory drafting before committing budget of their own. The real test is whether the program produces published, reproducible results by the time the credits run out — grant announcements are cheap; demonstrated mechanism discoveries or accelerated trials are the harder bar.